News articles about Alimera Sciences (NASDAQ:ALIM) have trended somewhat positive recently, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alimera Sciences earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 47.6335064670026 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the headlines that may have impacted Accern’s rankings:
- Ocular Drug Delivery Market: Manufacturers Collaborating with Hospitals to Bolster Positions (openpr.com)
- Connable Office Increased The Mosaic Co (MOS) Stake; Alimera Sciences Has 1 Sentiment – FlintDaily.com (nigeriatoday.ng)
- Age-Related Macular Degeneration (AMD) Market Identifies the Key Drivers of Growth and Challenges of the Key Industry Players (openpr.com)
- RSI Alert: Alimera Sciences, Inc. (ALIM) Now Oversold – Nasdaq Chronicle (nasdaqchronicle.com)
Alimera Sciences (ALIM) traded up $0.07 during trading on Friday, hitting $1.12. 213,131 shares of the stock traded hands, compared to its average volume of 145,072. The company has a quick ratio of 3.91, a current ratio of 4.07 and a debt-to-equity ratio of -0.64. Alimera Sciences has a 1 year low of $1.03 and a 1 year high of $1.71. The company has a market capitalization of $73.49, a P/E ratio of -3.50 and a beta of 1.58.
Several analysts have commented on the company. HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Alimera Sciences in a research note on Wednesday, November 22nd. ValuEngine cut Alimera Sciences from a “sell” rating to a “strong sell” rating in a report on Sunday, December 3rd. Finally, Zacks Investment Research raised Alimera Sciences from a “sell” rating to a “hold” rating in a report on Monday, January 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $3.38.
In other Alimera Sciences news, SVP Philip Ashman sold 25,500 shares of the stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $1.20, for a total transaction of $30,600.00. Following the sale, the senior vice president now directly owns 12,750 shares in the company, valued at approximately $15,300. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO C. Daniel Myers sold 52,900 shares of Alimera Sciences stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $1.23, for a total transaction of $65,067.00. Following the sale, the chief executive officer now owns 154,411 shares in the company, valued at $189,925.53. The disclosure for this sale can be found here. In the last quarter, insiders sold 184,704 shares of company stock valued at $224,432. Insiders own 14.70% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by BBNS and is owned by of BBNS. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://baseballnewssource.com/2018/03/17/alimera-sciences-alim-given-media-impact-score-of-0-18/2001348.html.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.